Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 1/2 1

Status

Completed 22Recruiting 21Unknown 16Active not recruiting 16Terminated 11Withdrawn 8Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers 1Efficacy 1

Interventions

Carboplatin 75Cisplatin 73Bevacizumab 64Radiotherapy 57Drug Therapy 56Capecitabine 56tislelizumab 54Oxaliplatin 54Gemcitabine 46toripalimab 45Paclitaxel 45Specimen Handling 43sintilimab 39pembrolizumab 39anlotinib 38Cyclophosphamide 33130-nm albumin-bound paclitaxel 32Magnetic Resonance Spectroscopy 27Injections 27camrelizumab 26Pemetrexed 26Surgical Procedures, Operative 25lenvatinib 23Docetaxel 23Biopsy 23apatinib 22Etoposide 22Immune Checkpoint Inhibitors 21S 1 (combination) 20Fluorouracil 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Not yet recruiting × niraparib × Clear all
NCT06237205 2024-02-01

Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency

Korea University Anam Hospital

Phase 2 Not yet recruiting
33 enrolled

Efficacy

NCT05232006 2022-03-08

PALB2-PARPi-01

Assistance Publique - Hôpitaux de Paris

Phase 2 Not yet recruiting
12 enrolled
Breast

Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers

Data powered by HemOnc (CC BY 4.0) Colophon ⚡